Company intelligence / Profile preview
ITabMed Ltd.
Shanghai*, Shanghai, Chinaitabmed.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ITabMed’s lead programs A‑319 and A‑337 are in Phase 1 clinical trials. Early results from two Phase 1 studies of A‑319 in relapsed/refractory B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma have shown an excellent safety profile and promising anti-tumor responses during dose escalation. The IND for A‑337, targeting EpCAM for solid tumors, has been approved by the NMPA[5].
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesTrispecific antibodiesT-cell engagers (BiTE, TriTE)Monoclonal antibodiesFusion recombinant proteins (Fc-dimer)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ITabMed Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITabMed Ltd..